Mediwhale

What Mediwhale does

Mediwhale is an AI-powered health diagnostics company that uses non-invasive retinal scans to predict the risk of cardiometabolic diseases. By leveraging deep learning, Mediwhale can identify future disease risks before symptoms appear. Founded in 2016, the company is committed to making preventive care more affordable, accessible, safe, and convenient. Mediwhale leverages retinal imaging and AI to establish a new standard in early detection, personalized risk assessment, and preventive healthcare. Their AI is built on over 2.1M high-quality clinical data points, trained across diverse populations and imaging devices, and proven through 50+ peer-reviewed publications, global clinical studies, and third-party validations. Their solutions are commercially deployed and globally certified in 8 regions, adopted by many hospitals and clinics worldwide. The eye's intricate network of blood vessels mirrors systemic changes in the heart, brain, kidneys, and beyond, allowing advanced retinal imaging to provide a non-invasive, painless, and radiation-free method to assess vascular and metabolic health and unlock early markers of diseases.

Products

• Dr.Noon CVDA retina-based AI risk prediction solution that assesses future cardiovascular disease risk. It demonstrates predictive accuracy comparable to heart CT scans in evaluating cardiovascular events. It is the world’s first AI-powered solution utilizing retinal imaging to assess cardiovascular risk.
• Dr. Noon FundusA retina-based AI solution that diagnoses retinal abnormalities. By analyzing a single retinal photograph, it automatically detects three types of eye diseases: Glaucoma, Cataracts, and Retinal diseases.
• Dr. Noon CKDA retina-based AI solution that predicts the future risk of chronic kidney disease.

Key capabilities

• Clinically Proven and Powerful AI
• Commercially Deployed and Globally Certified
• Designed to Fit Seamlessly into Real-world Healthcare
• Safe, radiation-free test
• Completed in minutes
• Instant, accurate results
• High Accuracy (for Dr. Noon CVD, comparable to heart CT)
• Non-Invasive
• Cost-Effective

Use cases

• Early detection of cardiometabolic diseases
• Personalized risk assessment
• Preventive healthcare
• Cardiovascular disease risk assessment
• Diagnosis of retinal abnormalities (Glaucoma, Cataracts, Retinal diseases)
• Chronic kidney disease risk prediction
• Metabolic dysfunction associated steatotic liver disease prediction (research in progress)
• Cognitive disorder prediction (research in progress)

AI approach

Mediwhale leverages retinal imaging and AI to establish a new standard in early detection, personalized risk assessment, and preventive care for cardiometabolic diseases. Their AI is trained on over 2.1M high-quality clinical data points across diverse populations and imaging devices. They develop AI solutions like Dr. Noon CVD for cardiovascular risk prediction and Dr. Noon Fundus for diagnosing retinal abnormalities (Glaucoma, Cataracts, Retinal diseases). They are also researching AI solutions for chronic kidney disease, metabolic dysfunction associated steatotic liver disease, and cognitive disorders.

Tech named: deep learning, deep learning neural network, machine learning

Industries served

• Healthcare

What it says sets it apart

• World's first regulatory-approved AI solution for cardiovascular risk assessment using retinal imaging
• Leverages over 2.1M high-quality clinical data points for AI training
• Proven through 50+ peer-reviewed publications, global clinical studies, and third-party validations
• Certified in 8 regions and adopted by many hospitals and clinics worldwide
• Non-invasive, painless, and radiation-free method
• Early detection of diseases before symptoms appear
• Cost-effective compared to conventional screenings

Funding rounds we track

From the AI funding tracker — rounds as reported by the linked publications.